Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2022 Earnings Conference Call May 4, 2022 11:30 AM ET Company Participants Brett Monia - Founder, CEO & Director Elizabeth Hougen - EVP, Finance & CFO Eugene Schneider - EVP & Chief Clinical Development Officer Eric Swayze - EVP, Research Onaiza Cadoret - EVP and Chief Product Strategy & Operations Officer Conference Call Participants Yanan Zhu - Wells Fargo Securities Brendan Smith - Cowen and Company Luca Issi - RBC Capital Markets Jessica Fye - JPMorgan Chase ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of i ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2021 Results Earnings Conference Call February 24, 2022 11:30 AM ET Company Participants Jennifer Capuzelo - Director of Investor Relation Brett Monia - Founder & CEO Beth Hougen - Chief Financial Officer Richard Geary - Executive Vice President & Chief Development Officer Eric Swayze - Executive Vice President of Research Onaiza Cadoret-Manier - Executive Vice President & Chief Product Strategy & Operations Officer Conference Call Participants Gary Nachman - BMO ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2021 Earnings Conference Call November 3, 2021 11:30 AM ET Company Participants Jennifer Capuzela - Director of Investor Relation Brett Monia - Founder, CEO & Director Beth Hougen - Chief Financial Officer Richard Geary - EVP & Chief Development Officer Onaiza Cadoret-Manier - EVP and Chief Corporate Development & Commercial Officer Eric Swayze - EVP of Research Conference Call Participants Yale Jen - Laidlaw & Co Chi Meng Fong - BofA Securities Yanan Zhu - Wells ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2021 Earnings Conference Call August 4, 2021 11:30 AM ET Company Participants David Nakasone - IR Brett Monia - Founder, CEO & Director Elizabeth Hougen - EVP, Finance & CFO Richard Geary - EVP & Chief Development Officer Eric Swayze - EVP, Research Onaiza Cadoret-Manier - EVP & Chief Corporate Development & Commercial Officer Conference Call Participants Jason Gerberry - Bank of America Merrill Lynch Luca Issi - RBC Capital Markets Brendan Smith - Cowen and Comp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or othe ...

| --- | --- | --- | --- | --- | --- | |------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2021 Annual Meeting of | | | | | | | Stockholders Corporate | | | | | | | Presentation | | | | | | | June 2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Changes to the Ionis Board of Directors (1 of 2) 2 Departures Stanley T. Crooke, M.D., Ph.D. Ionis Founder and Executive Chairman 30 Years of ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2021 Earnings Conference Call May 5, 2021 11:30 AM ET Company Participants Wade Walke - VP, IR Brett Monia - CEO Beth Hougen - CFO Richard Geary - EVP of Development Eric Swayze - EVP of Research Onaiza Cadoret - Chief Corporate Development and Commercial Officer Conference Call Participants Luca Issi - RBC Yaron Werber - Cowen Yanan Zhu - Wells Fargo Yale Jen - Laidlaw and Company Jason Gerberry - Bank of America Jessica Fye - JP Morgan Mani Foroohar - SVB Leeri ...